NCT05044988View on ClinicalTrials.gov

A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Interventions
DRUG

HS-10342

HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY